Zenotech Laboratories (BOM:532039) Stock Based Compensation: ₹0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532039 Zenotech Laboratories Ltd BOM:532039
74 GF Score
Price ₹46.25
GF Value ₹64.76
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Zenotech Laboratories Stock Based Compensation?

Zenotech Laboratories BOM:532039 -1.47% 74 Stock Based Compensation is ₹0.0 Mil as of Jun. 2026. GuruFocus rates BOM:532039 with a GF Score™ of 74/100 and a GF Value™ of ₹64.76 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Zenotech Laboratories's Stock Based Compensation for the three months ended in Jun. 2026 was ₹0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0.0 Mil.

Zenotech Laboratories Stock Based Compensation Related Terms

Zenotech Laboratories Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Zenotech Laboratories's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenotech Laboratories Stock Based Compensation Chart

Zenotech Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zenotech Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:532039
74GF Score
Zenotech Laboratories Ltd BOM:532039
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenotech Laboratories Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

What does a Stock Based Compensation of ₹0.0 Mil mean?
Zenotech Laboratories (BOM:532039) has a Stock Based Compensation of ₹0.0 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zenotech Laboratories and its competitors.
Is Zenotech Laboratories' Stock Based Compensation too high?
Zenotech Laboratories' current Stock Based Compensation is ₹0.0 Mil. Overall, Zenotech Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenotech Laboratories' Stock Based Compensation compare to ZTS?
Zenotech Laboratories' Stock Based Compensation of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zenotech Laboratories and its competitors. Zenotech Laboratories's current Stock Based Compensation is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenotech Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zenotech Laboratories (BOM:532039) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹64.76, compared to a current price of ₹46.25 — trading 28.6% below its estimated fair value. The current Stock Based Compensation is ₹0.0 Mil. Zenotech Laboratories' overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Zenotech Laboratories (BOM:532039), the current Stock Based Compensation is ₹0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zenotech Laboratories (BOM:532039) Overvalued in 2026?

Based on GuruFocus' analysis, Zenotech Laboratories stock appears to be undervalued. The current stock price of ₹46.25 is trading 28.6% below its estimated GF Value™ of ₹64.76. GuruFocus considers Zenotech Laboratories to be Modestly Undervalued.

Key valuation signals for BOM:532039:

  • Stock Based Compensation: ₹0.0 Mil
  • GF Value™: ₹64.76 vs. price of ₹46.25 (28.6% below fair value)
  • GF Score™: 74/100 with 1 warning sign

No single metric tells the full story. See the BOM:532039 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zenotech Laboratories Business Description

Address Survey No. 250-252, Turkapally Village, Shamirpet Mandal, RR District, Hyderabad, TG, IND, 500 078
Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.
74GF Score

Get the complete analysis for BOM:532039

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹46.25
Price
₹64.76
GF Value